1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Qualitative evaluation of perfusion parametric maps in full-dose (0.1-mmol/kg) and half-dose (0.05-mmol/kg) contrast groups processed with Bayesian and cSVD methodsa
Bayesian cSVD Wilcoxon Test (P Value) Spearman Rank (r), 95% CI Full-dose CBF 4, 3–4 4, 3–4 .76 0.84, 0.63–0.93 CBV 4, 3–4 4, 3–4 .6 0.69, 0.35–0.87 MTT 4, 3–4 3, 3–4 .12 0.53, 0.32–0.76 Half-dose CBF 4, 3–4 3, 3–4 .27 0.66, 0.31–0.85 CBV 3, 3–4 3, 2–4 .02b 0.4, 0.17–0.74 MTT 3, 3–4 3, 2–3 .004b 0.12, 0.04–0.54